NewEdge Advisors LLC Raises Holdings in Corcept Therapeutics Incorporated $CORT

NewEdge Advisors LLC boosted its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 727.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,364 shares of the biotechnology company’s stock after acquiring an additional 8,232 shares during the quarter. NewEdge Advisors LLC’s holdings in Corcept Therapeutics were worth $377,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Avidity Partners Management LP purchased a new position in shares of Corcept Therapeutics during the 4th quarter worth $766,000. Norges Bank acquired a new stake in shares of Corcept Therapeutics during the 4th quarter worth about $24,213,000. Caitong International Asset Management Co. Ltd purchased a new stake in Corcept Therapeutics in the 4th quarter valued at about $8,757,000. Jefferies Financial Group Inc. purchased a new stake in Corcept Therapeutics in the 4th quarter valued at about $2,021,000. Finally, BOKF NA acquired a new position in Corcept Therapeutics in the fourth quarter valued at about $1,061,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In other news, Director David L. Mahoney sold 103,606 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $118.25, for a total value of $12,251,409.50. Following the completion of the transaction, the director owned 1,133,539 shares of the company’s stock, valued at approximately $134,040,986.75. This trade represents a 8.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider William Guyer sold 16,300 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $113.43, for a total transaction of $1,848,909.00. Following the completion of the transaction, the insider owned 3,985 shares of the company’s stock, valued at $452,018.55. This trade represents a 80.35% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 520,146 shares of company stock valued at $48,903,764. Corporate insiders own 20.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on CORT shares. Zacks Research raised shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a report on Thursday, May 28th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a research report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $138.17.

Corcept Therapeutics Stock Performance

CORT opened at $122.25 on Monday. The stock’s 50-day moving average price is $97.39 and its 200 day moving average price is $64.76. Corcept Therapeutics Incorporated has a 12-month low of $28.66 and a 12-month high of $123.44. The firm has a market cap of $13.22 billion, a price-to-earnings ratio of 291.08 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. The company had revenue of $256.15 million during the quarter, compared to analysts’ expectations of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.Corcept Therapeutics’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same period last year, the business posted $0.29 EPS. On average, research analysts forecast that Corcept Therapeutics Incorporated will post 1.77 earnings per share for the current year.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks sharply raised long-term earnings forecasts. The firm increased its FY2026 EPS estimate to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also raised, including Q1 2027 to $0.11 from a projected loss of $0.17 and Q2 2028 to $1.17 from $0.69. These revisions signal expectations for accelerating profitability.
• Positive Sentiment: Recent operating results provide support for the bullish outlook. Corcept’s latest reported quarter produced $0.36 in EPS versus the $0.02 consensus estimate, while revenue of $256.15 million exceeded expectations of $221.15 million and grew 31.7% year over year.
• Positive Sentiment: Analyst sentiment and price targets remain constructive. Recent coverage includes Buy or Overweight ratings and price targets ranging from $150 to $165, while the reported consensus rating is “Moderate Buy” with a $138.17 target. An investment analysis also argued that the launch of Lifyorli and continued Korlym growth could drive revenue growth, margin expansion and further EPS upside. Like The Knicks, Corcept Rebounded And Is Crushing It
• Neutral Sentiment: Zacks maintained a “Hold” rating. The improved earnings estimates are encouraging, but the unchanged rating suggests the analyst views the stock’s substantial rally and high valuation as partly reflected in the price.
• Negative Sentiment: Director David Mahoney sold 103,606 shares for approximately $12.25 million. The transaction reduced his ownership by 8.37%, although he still retained more than 1.13 million shares. The sale could create short-term sentiment pressure, but it does not necessarily indicate a change in the company’s fundamentals. Insider Selling: Corcept Therapeutics Director Sells Stock

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.